Navigation Links
AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
Date:5/3/2013

REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2013 financial results after market close on Wednesday, May 8, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on May 8, 2013 to discuss the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link in the Event Calendar page.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investors page of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced results from two Phase 3 clinical trials for the NanoTab System, and a third Phase 3 study has completed enrollment, with data expected in the second quarter of 2013.  A New Drug Application submission is planned for the third quarter of 2013. AcelRx recently announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the release and anticipated timing of additional NanoTab System clinical trial data, anticipated timing of completion of AcelRx Pharmaceuticals' current clinical trials, submission of the NDA, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; its ability to obtain sufficient financing to complete development and registration of its product candidates in the United States and Europe; its ability to obtain and maintain regulatory approvals of its product candidates; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Annual Report on Form 10-K filed with the SEC on March 12, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
2. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
3. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
4. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
5. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
6. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. AcelRx Pharmaceuticals Provides Clinical Trial Updates
8. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
9. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
11. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... ... needs in the field of urology, today announced that Naveen Divakaruni, D.O., Advocate ... Excellence. The designation recognizes that Dr. Divakaruni has achieved a high level of ...
(Date:5/21/2020)... ... ... Labyrinthe Labs has announced the launch of its brand new and ground-breaking ... for fast-action relief of joint and muscle soreness, Lefa is botanically powered by a ... and muscles. , According to the National Institutes of Health , approximately ...
(Date:5/17/2020)... ... 2020 , ... The Sea Cucumber-derived triterpenoid glycoside Frondoside A, which has been ... the Sea Cucumber in a proprietary process to give SeaCare Dietary Supplement ... and time again: “You get what you pay for.” It is usually in reference ...
Breaking Medicine Technology:
(Date:5/27/2020)... LAUREL, N.J. (PRWEB) , ... May 27, 2020 ... ... contract manufacturer, announces that it is now manufacturing face shields to be ... novel coronavirus that causes COVID-19. These face shields are single use, made to ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... of Washington Professor of Bioengineering, Founder & Editor of scientific journal WATER, ... ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water , * , During ...
(Date:5/26/2020)... ... , ... Today TRC Companies (“ TRC ”) announced the release of its ... owners and leaders assess whether their organizations are prepared to move forward as the ... intended to assist business leaders evaluate their readiness relative to CDC guidance and provides ...
(Date:5/25/2020)... ... ... Winemaker Grant Long Jr. is introducing three Toilet Paper Reserve wines. “These are ... complicated times,” he said, in announcing the new wines. The wines are 2019 Chardonnay ... Wine Blend are sourced in the Napa Valley; the Grenache comes from the El ...
(Date:5/21/2020)... Minn. (PRWEB) , ... May 21, 2020 , ... ... medical device manufacturer, announces its first milestone to deliver over one million FDA-compliant ... eight weeks. Summit Medical Face Shields meet the critical need for personal protective ...
Breaking Medicine News(10 mins):